Article Sidebar

PDF
Date Published: 08/07/2022
Online Published: 08/07/2022
Abstract Views: 161
Views PDF: 79
DOI: https://doi.org/10.55046/vjrnm.35.604.2019
Issue
No. 35 (2019)
Section
Scientific research
How to Cite
Bui, Q. B., Le, N. H., & Lam, K. (2022). Imaging characteristics and diagnostic value of 18F-FDG PET/CT in post-operative differentiated thyroid cancer patients with elevated serum thyroglobulin and negative 131I whole body scan. Vietnamese Journal of Radiology and Nuclear Medicine, 35, 59-67. https://doi.org/10.55046/vjrnm.35.604.2019

Imaging characteristics and diagnostic value of 18F-FDG PET/CT in post-operative differentiated thyroid cancer patients with elevated serum thyroglobulin and negative 131I whole body scan

Bui Quang Bieu1, Le Ngoc Ha1, Lam Khanh1,
1 Military Central Hospital 108

Main Article Content

Abstract

SUMMARY


To evaluate the imaging characteristics and diagnostic value of 18F-FDG PET/CT in post-operative differentiated thyroid cancer (DTC) patients with elevated serum thyroglobulin and negative 131I whole body scan.
Materials and method: we performed a cross-sectional descriptive study on 109 post-surgical DTC patients. All patients underwent 18F-FDG
PET/CT scan to look for recurrence/metastasis. PET/CT results were compared with hisopathology and clinical follow-up to determine its diagnostic values.
Results: 294 lesions were identified in PET/CT with mean diameter and SUV were 14.0 mm và 9.3 g/ml, respectively. Lesions were most found in
cervical lymphnode, mediastinum, thyroid bed and lung. PET/CT was positive in 78% of patients with true positive, false positive, true negative and false negative rates were 92.9; 7.1; 75 and 25%; respectively. Sensitivity, specificity
and accuracy of PET/CT in detecting recurrent/metastatic DTC were 92.9; 75
and 89%, respectively. SUVmax threshold of 5.9 ng/ml was the most suitable to determine recurrent/metastatic lesions in PET/CT.
Conclusions: 18F-FDG PET/CT is a valuable imaging tool to diagnose recurrence/metastasis in DTC patient with elevated serum thyroglobulin and negative 131I whole body scan.

Article Details

Keywords

18F-FDG PET/CT, differentiated thyroid cancer, elevated thyroglobulin, negative131I whole body scan

References

TÀI LIỆU THAM KHẢO
1. Cancer Today [online] Available at: http://gco.iarc.fr/today/home [Accessed 31 December 2018].
2. Basu S, Dandekar M, Joshi A, D’Cruz A (2015). Defining a rational step-care algorithm for managing thyroid carcinoma patients with elevated thyroglobulin and negative on radioiodine scintigraphy (TENIS): considerations and challenges towards developing an appropriate roadmap. Eur J Nucl Med Mol Imaging, 42, 1167–1171.
3. Caetano R, Bastos CRG, de Olivera IAG et al (2016). Accuracy of positron emission tomography and positron emission tomography-CT in the detection of differentiated thyroid cancer recurrence with negative 131I wholebody scan results: A meta-analysis. Head Neck, 38, 316–327.
4. Chung JK, So Y, Lee JS et al (1999). Value of FDG PET in papillary thyroid carcinoma with negative l3lI wholebody scan. J NucI Med, 40, 986-992.
5. Vural GU, Akkas BE, Erkamak N et al (2012). Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131-I whole-body scan and elevated thyroglobulin levels correlation with clinical and histopathologic characteristics and long-term follow-up data. Clin Nucl Med, 37, 953-959.
6. Kunawudhi A, Pak-art R, Keelawat S et al (2012). Detection of subcentimeter metastatic cervical lymph node by 18F-FDG PET/CT in patients with well-differentiated thyroid carcinoma and high serum thyroglobulin but negative 131I whole-body scan. Clin Nucl Med,37(6), 561-7.
7. Iagaru A, Kalinyak JE, McDougall R (2007). F-18 FDG PET/CT in the management of thyroid cancer. Clin Nucl Med, 32, 690–695
8. Na SJ, Yoo IR, O JH et al (2012). Diagnostic accuracy of 18F-fluorodeoxyglucose positron emission tomography/ computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative 131I whole body scan: evaluation by thyroglobulin level. Ann Nucl Med, 26:26–34.
9. Ozkan E, Aras G, Kucuk NO (2013). Correlation of 18F-FDG PET/CT findings with histopathological results in differentiated thyroid cancer patients who have increased thyroglobulin or antithyroglobulin antibody levels and negative 131-I whole-body scan results. Clin Nucl Med, 38, 326-331.
10. Ha LN, Bieu BQ, Son MH (2016). Value of dedicated head and neck 18F-FDG PET/CT protocol in detecting recurrent and metastatic lesions in post-surgical differentiated thyroid carcinoma patients with high serum thyroglobulin level and negative 131I whole-body scan. Asia Oceania J Nucl Med Biol, 4(1), 12-18.
11. Stangierski A1, Kaznowski J, Wolinski K et al (2016). The usefulness of fluorine-18 fluorodeoxyglucose PET in the detection of recurrence in patients with differentiated thyroid cancer with elevated thyroglobulin and negative radioiodine whole-body scan. Nucl Med Commun, 37(9), 935-8
12. Choi SJ, Jung KP, Lee SS et al (2016). Clinical usefulness of F-18 FDG PET/CT in papillary thyroid cancer with negative radioiodine scan and elevated thyroglobulin level or positive anti-thyroglobulin antibody, Nucl Med Mol Imaging, 50, 130–136.